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KATHERINE FRANCES VALLÈS 
ABSTRACT 
The 2009 Influenza A (H1N1) virus quickly became a pandemic and a threat to the health 
of many across the globe. H1N1 was able to preferentially bind to pneumocytes in the 
lower lung, resulting in atelectasis, surfactant disruption, and eventual acute respiratory 
distress syndrome (ARDS). Management of ARDS during this time included non-
ventilatory and ventilatory techniques such as conservative fluid management, prone 
positioning, differing PEEP levels, and Extracorporeal Membrane Oxygenation (ECMO). 
High cost, unequal global access to ECMO centers, and complication rates present 
challenges to future ECMO expansion. Despite this, the available information supports 
the use of ECMO for H1N1-associated ARDS. Future studies and simulations should be 
conducted to expand the knowledge base on using ECMO as a treatment for pandemic 
influenza-associated ARDS, with particular attention on bridging gaps in access for the 
most vulnerable and affected populations. 
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INTRODUCTION 
In the spring of 2009, reports of a deadly “swine” flu were growing rapidly in 
Mexico and the United States (“CDC Novel H1N1 Flu | The 2009 H1N1 Pandemic,” 
n.d.). Within months, this virus had spread to almost every country in the world and had 
infected hundreds of millions of people. This virus was found to be a novel strain of 
influenza A (H1N1). An infection is considered a pandemic when there is simultaneous 
transmission taking place worldwide, specifically out-of-season transmission for an 
influenza pandemic (“WHO | The classical definition of a pandemic is not elusive,” n.d.). 
The 2009 H1N1 flu pandemic became one of the most ominous threats to public health in 
the 21st century. This virus showed that despite crucial advancements in infectious 
disease control and public health preventions, the world remains susceptible to fast-
moving, highly contagious viruses. The speed at which the 2009 “swine” flu pandemic 
spread globally was unprecedented (Al Hajjar & McIntosh, 2010). While it was not the 
deadliest pandemic, there is much to be learned from the physiological manifestations 
and treatments that occurred. It is estimated that of the 284,400 deaths, 201,200 were 
attributed to respiratory causes including acute respiratory distress syndrome (ARDS) 
(“CDC Novel H1N1 Flu | The 2009 H1N1 Pandemic,” n.d.). The threat for future 
respiratory-related pandemics remains high and it is important to research the use and 
efficacy of treatments such as extracorporeal membrane oxygenation (ECMO) during the 
2009 H1N1 pandemic to best prepare for future pandemics of this kind.  
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Influenza  
Influenza has been present for centuries with larger pandemics such as the 1918 
“Spanish” flu, the 1957 “Asian” flu, the 1968 “Hong Kong” flu, and the 2009 “swine” 
flu. Influenzas are contagious diseases which are spread through droplet transmission 
such as coughing or sneezing. Influenzas are characterized by segmented, negative-strand 
RNA genomes and can be classified by type (A, B, or C) and subtype of the surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA) (Bouvier & Palese, 2008). 
Type A is the most common and virulent among humans and has been the type 
responsible for all influenza pandemics. Hemagglutinin is a protein that regulates viral 
attachment to the host cell and neuraminidase is an enzyme that regulates release of the 
virus from the infected cell (Appendix: Figures - Figure 1). The 2009 “swine” flu 
pandemic was characterized as Type A, hemagglutinin subtype 1, and neuraminidase 
subtype 1. The 1918 “Spanish” flu was A(H1N1), the 1957 “Asian” flu was A(H2N2), 
and the 1968 “Hong Kong” flu was A(H3N2).  
 
The different types of influenza are caused from reassortment, which is the 
exchange of viral RNA segments between influenza viruses and antigenic variation, 
which can be in forms of antigenic shift and/or antigenic drift (Steel & Lowen, 2014). 
Antigenic shift is a process in which whole genetic segments of the hemagglutinin 
protein, and sometimes the neuraminidase enzyme, are exchanged with novel, 
transmissible subtypes from animal sources. Antigenic shifts are the cause of pandemics 
among the human population (Chang, Southard, & Sullivan, 2010). Antigenic drift is a 
process in which point mutations occur at the hemagglutinin and/or neuraminidase 
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antibody binding sites, creating new strains and preventing the host antibodies from 
effectively binding and signaling the immune system of invasion (Chang et al., 2010). 
These processes allow the virus to evade the host’s immune system. These reassortment 
processes occur instantaneously and create dramatic changes in a virus, allowing 
effective infection into human populations. 
 
Seasonal Influenzas 
Seasonal influenzas, which the globe has become accustomed to, present with 
similar symptoms each year: fever, chills, muscle pains, weakness, and respiratory 
ailments (Morens, Taubenberger, Harvey, & Memoli, 2010). Common retroviral 
therapies such as oseltamivir, zanamivir, and peramivir are used as treatments for the flu 
(CDC, 2017). The WHO estimates that the flu results in ~1 billion cases per year and 
between 300,000 and 500,000 deaths (“WHO | Influenza,” n.d.). Vaccines are widely 
available to prevent seasonal flu, but it is challenging for scientists to estimate the exact 
genetic makeup of the strain each year. While most influenzas appear in temperate 
regions during winter months, the 2009 pandemic was unique in that it developed in the 
spring and lasted throughout the summer months (Chang et al., 2010). As seen in the 
2009 H1N1 pandemic, it is possible and probable that mutations and reassortments can 
occur and take advantage of global susceptibility. 
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Pandemic 2009 H1N1 relation to 1918 “Spanish” Flu 
The 1918-1919 influenza was quoted to be the “Mother of All Pandemics;” 
infecting over 1/3 of the global population and resulting in over 50 million deaths 
worldwide (Taubenberger & Morens, 2006). Researchers thought that the 1918 pandemic 
disappeared from human circulation when the 1957 H2N2 “Asian” flu did not show 
resemblance to the 1918 pandemic. In 1977, however, these strains reemerged and have 
been present since. Genes from H1N1, H2N2, and H3N2 viruses originating in the 1918 
pandemic have been found in almost all influenzas to this day, including the 2009 H1N1 
pandemic.  
Similar to the 1918 pandemic, the 2009 H1N1 pandemic was considered to be a 
novel virus. The 1957 and 1968 pandemics both showed genetic descendants of the 1918 
virus, but the 2009 H1N1 was more genetically complex. The 2009 virus showed triple 
reassortment, updating its genome through avian, swine, and eventually human influenza 
genes (Morens et al., 2010). While the 1957 and 1968 pandemics exhibited a U-shaped 
mortality curve, where mortality was highest among the young and the old, the 2009 
virus did not follow this curve. Instead, the 2009 virus was similar to the 1918 virus in 
that it exhibited a W-shaped curve, where relatively young and healthy adults between 
the ages of 20-40 years were perishing at high rates (Appendix: Figures – Figure 2). It is 
hypothesized that older adults had lower attack rates in 2009 due to circulating H1N1 
viruses throughout their lifetime and more exposure to seasonal influenzas, compared to 
the more naïve populations (Morens et al., 2010). Regardless of these potential 
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protections, the 2009 H1N1 virus resulted in over 284,400 deaths and was present in 214 
countries and overseas territories (“CDC Novel H1N1 Flu | 2009 H1N1,” n.d.).  
 
 
2009 H1N1 Development 
The virus began in Mexico and moved to the United States, with the first 
confirmed case of the novel 2009 H1N1 swine flu being identified on April 15, 2009 in a 
10-year-old boy in California. This virus was composed of genes originating from four 
different influenza virus sources: North American swine influenza virus, North American 
avian influenza virus, human influenza virus, and Asian and European swine influenza 
virus. The complex genetic makeup of the 2009 H1N1 virus made it a challenging task 
for researchers to identify cases and track the source of transmission; it took nearly one 
month to conclude that 2009 H1N1 was transmitted human to human. During this period 
the 2009 H1N1 virus spread around the globe rapidly and on June 11, 2009 the World 
Health Organization (WHO) declared a global pandemic of the 2009 H1N1 influenza 
(“WHO | World now at the start of 2009 influenza pandemic,” n.d.). By June 25, 2009, 
the CDC estimated that the United States alone had 1 million cases of 2009 H1N1 (“CDC 
Novel H1N1 Flu | The 2009 H1N1 Pandemic,” n.d.), increasing to over 60.8 million by 
the end of the pandemic (“Past Pandemics | Pandemic Influenza (Flu) | CDC,” 2018). 
Swine flu spread to almost every country in the world by the end of the pandemic. 
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2009 H1N1 Affected Populations 
 The 2009 influenza pandemic was unique in that it predominantly affected 
children and young adult populations as compared to seasonal influenzas. The median 
age of affected populations in Canada, the United States, Chile, Japan and the United 
Kingdom was 12-17 years old and only 5% of hospitalized patients in the USA from 
April to mid-June 2009 were over 65 years old (Girard, Tam, Assossou, & Kieny, 2010).  
It is hypothesized that cytokine storm may have played a role in the burden of 
disease among younger patients, as one study found that levels of IL-1, IL-6, TNF-, IL-
8, MCP-1, MIP1-, and IP-10 were expressed at extremely high levels in lung tissues of 
50 fatal H1N1 cases in 2009 (Gao et al., 2013). A cytokine storm is an unbalanced 
cytokine response involving an aggressive pro-inflammatory response and inadequate 
control of the anti-inflammatory response, resulting in a hyper-activating immune system 
(Qiang Liu, Zhou, & Yang, 2016). Cytokine storms can lead to damage of vascular 
surfaces and result in edema, capillary leakage, organ failure, and death (Sivro, Stein, & 
McKinnon, 2011).As younger populations have stronger immune systems than older 
adults, the likelihood of a cytokine storm is higher. Additionally, the W-shaped mortality 
curve of the 2009 virus (Appendix: Figures – Figure 3) showed that relatively young and 
healthy adults were perishing at high rates. It is hypothesized that younger populations 
were more susceptible to the 2009 virus as they had not been exposed to as many 
influenza strains in their lifetime (Morens et al., 2010). 
 In addition to younger populations, pregnant women were among those overly 
burdened by H1N1. As compared to season influenzas, the larger, pandemic influenzas 
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have shown that pregnant women are disproportionately burdened by disease. Changes in 
immunosuppression and both cardiovascular and respiratory physiology during 
pregnancy contribute to the increased susceptibility to severe outcomes related to H1N1 
seen in pregnant women (Satpathy, Lindsay, & Kawwass, 2009). In a study summarizing 
data from 788 pregnant women from 50 state and local health departments in the United 
States, it was found that although pregnant women make up only 1% of the population, 
they represented 5% of the 2009 H1N1 deaths (Siston et al., 2010). Underlying causes 
such as asthma were seen in 43.5% of the deaths and 25.6% of the ICU admissions 
(Siston et al., 2010). Additionally, nearly one-third of pregnant women with H1N1 were 
hospitalized, and most were due to respiratory distress (Satpathy et al., 2009).  
 
Acute Respiratory Distress Syndrome 
Acute respiratory distress syndrome (ARDS) is a form of acute life threatening 
respiratory failure in which there is acute onset of pulmonary edema of non-cardiogenic 
origin, which decreases the compliance of the lung and presents with bilateral 
parenchymal pulmonary infiltrates on chest radiograph and a PaO2/FiO2 ratio ≤200 
mmHg (Fanelli et al., 2013). The main cause of ARDS is sepsis with other causes 
including pneumonia, aspiration, drugs, trauma, embolism, and burns (“ARDS | National 
Heart, Lung, and Blood Institute (NHLBI),” n.d.). During the 2009 pandemic, however, 
the WHO found that H1N1 was responsible for 17.3 – 56% of ARDS mortalities (Zhang 
et al., 2012). Additionally, among H1N1 patients, ARDS was the main cause of death 
(Zhang et al., 2012).   
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 During the pandemic, respiratory causes posed the largest threat to life. Of the 
284,400 estimated deaths attributed to both cardiovascular and respiratory causes, 
201,200 (95% CI: 105,700 – 395,600) were due to respiratory causes alone (Dawood et 
al., 2012). Almost all of the deaths were in people younger than 65 years old and over 
half of the deaths occurred in southeast Asia and Africa. The most common respiratory 
pathophysiological manifestation of 2009 H1N1 was acute respiratory distress syndrome 
(ARDS). ARDS is diagnosed based on the following criteria: acute onset of bilateral 
alveolar infiltrates on chest radiograph, PaO2/FiO2 ratio ≤ 200 mmHg, and pulmonary 
artery occlusion pressure of 18 mmHg or no clinical evidence of left atrial hypertension 
(Tathagat, Mathew, & deBoisblanc, n.d.). The H1N1 virus causes increased inflammation 
of alveoli and subsequent hypoxemia, leading to pulmonary edema (Zhang et al., 2012). 
Given that researchers’ models suggest overall deaths ranged from 151,700 – 575,400 
deaths (“First Global Estimates of 2009 H1N1 Pandemic Mortality Released by CDC-
Led Collaboration | Spotlights (Flu) | CDC,” 2017), Dawood et al’s estimate that 201,200 
respiratory deaths occurred would suggest that almost half, but perhaps all, deaths were 
due to ARDS, providing an ominous déjà-vu from the deadly experience in 1918. 
Young adults, pregnant women, and those with preexisting medical conditions 
were at the highest risk of ARDS from H1N1 and were the most likely to experience 
severe hypoxemia and death. Most cases of 2009 H1N1-related ARDS required intensive 
care unit (ICU) hospitalization (Tathagat et al., n.d.) and an overall mortality rate was 
found to be 58% in one retrospective study conducted in Germany (Töpfer et al., 2014). 
In this study, H1N1-associated ARDS was found to differ from non-H1N1-associated 
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ARDS in that those with 2009 H1N1 had substantially longer recovery times for 
pulmonary gas exchange, more frequent demand of extracorporeal lung support, and 
longer ICU stays (Töpfer et al., 2014).  
 
Extracorporeal Membrane Oxygenation 
Treatments for H1N1-caused ARDS range based on access to care and 
indications. Since its first successful use for respiratory failure in 1927, extracorporeal 
membrane oxygenation (ECMO) has become a salvage strategy for patients around the 
globe (Makdisi & Wang, 2015). ECMO is a process in which there is a modified heart-
lung machine that drains blood from a major vein, pumps the blood through a membrane 
lung (oxygenator), exchanges heat, and returns O2-rich, CO2-poor blood back into a 
major artery as in VA-ECMO or a major vein in VV-ECMO (Ventetuolo & Muratore, 
2014) (Appendix: Figures – Figure 4). The goal of ECMO is to reduce strain on the 
cardiopulmonary system and to deliver O2 and remove CO2 from blood while the patient 
is recovering. ECMO has been used as a treatment for ARDS as a result of Influenza A 
(H1N1) virus infection since the start of the pandemic and has been shown to be an 
effective form of treatment in some studies (Kutleša et al., 2014), (ANZ ECMO 
Investigators & Davies, 2009), (Courouble et al., 2011). As it currently stands, there are 
only 126 ECMO programs registered with the Extracorporeal Life Support Organization 
(ELSO) in the United States, each of which are able to run only two ECMO machines at a 
time (Delaney et al., 2010). As it is predicted that the world will likely be presented with 
a pandemic influenza in the near future that could affect between 12-30% of the global 
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population (Delaney et al., 2010), it is necessary to learn from the 2009 H1N1 pandemic 
and the use of ECMO as a treatment for ARDS. This calls for the further exploration and 
research of ECMO as a treatment for H1N1-associated ARDS.   
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SPECIFIC AIMS AND OBJECTIVES 
 
The specific aims and objective of this thesis include a review of treatment options for 
H1N1-associated ARDS, with a specific emphasis on the use of ECMO. Discussion of 
minimization of adverse side-effects will be explored. Outcomes and the capacity to 
expand ECMO usage in future pandemics will be discussed.  
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SEARCH STRATEGIES 
PubMed was utilized as the primary database. A broad search for “Extracorporeal 
Membrane Oxygenation” and “Acute Respiratory Distress Syndrome” were done 
separately, each yielding 9,070 and 21,729 articles respectively. Search terms were 
combined and limited to the English language, which yielded 1,125 articles, and limited 
again to show only articles published in the last 20 years, yielding 980 articles. The Mesh 
terms for Extracorporeal Membrane Oxygenation, Acute Respiratory Distress Syndrome 
and Influenza A Virus were combined and the same limitations were placed, yielding 66 
articles with the following search term: ((("Extracorporeal Membrane 
Oxygenation"[Mesh]) AND "Influenza A Virus, H1N1 Subtype"[Mesh]) AND 
("Respiratory Distress Syndrome, Adult"[Mesh]) AND ( "1997/01/01"[PDat] : 
"3000/12/31"[PDat] ) AND English[lang]). The abstracts were scanned for relevance and 
articles were read fully. Analysis of bibliographies from relevant works was conducted in 
the search for additional articles on similar topics. Again, PubMed was utilized in similar 
search fashions to find articles relating to influenza biology, non-ventilatory and 
ventilatory lung management strategies, cost-effectiveness, and future concerns.  
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H1N1-ASSOCIATED ARDS: CAUSAL PATHWAY 
H1N1 Viral Attachment and Pro-Inflammatory Signaling 
 Humans are exposed to H1N1 via airborne droplets. When inhaled, droplets may 
settle on any of the respiratory mucosal epithelia. The neuraminidase protein on the 
H1N1 virus aids in the virus’ ability to find the appropriate receptor to bind to within the 
respiratory tract. The H1N1 viral life cycle begins when the hemagglutinin (HA) protein 
binds to a sialic acid-containing receptor on the host cell surface. Season influenzas 
predominantly bind to an α-2,6 sialic acid receptor, meaning that there is a bond to 
galactose at the α-2,6 position. Unlike most seasonal influenzas, the 2009 H1N1 
influenza showed preferential binding to the α-2,3 sialic acid receptors that are found 
predominantly in the lower respiratory tract. The α-2,6 receptors are found along the 
entire respiratory tract, while α-2,3 receptors are found mostly in the lower respiratory 
tract in distal bronchioles, type 2 pneumocytes, and alveolar macrophages (Cheng, To, 
Tse, Hung, & Yuen, 2012). 
 When bound and endocytosed, the virus is able to take over cell machinery and 
replicate quickly. In the process, H1N1 triggers increases in cytokines, chemokines, and 
pro-inflammatory markers. One study found that levels of IL-1, IL-6, tumor necrosis 
factor- (TNF-), IL-8, monocyte chemoattractant protein-1 (MIP-1), macrophage 
inflammatory protein 1- (MIP1-), and interferon inducible protein-10 (IP-10) were 
expressed at extremely high levels in lung tissues of 50 fatal H1N1 cases in 2009 (Gao et 
al., 2013) and other studies found that in addition to the mentioned cytokines and 
chemokines, IL-10 and IFN- were also elevated (Cheng et al., 2012), (K. Sun, Ye, Perez, 
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& Metzger, 2011), (Tu et al., 2010). IL-1, IL-6, IL-8, TNF-, MCP-1, MIP1-, IP-10, 
and IFN- are all related to proinflammatory responses in the innate immune system. IL-
10, however, is an anti-inflammatory cytokine (Moore, Malefyt, Coffman, & O’Garra, 
2001). This study found that 2009 H1N1 was able to induce an exacerbated local immune 
response and apoptosis in lung tissue of autopsied patients based on histological samples 
(Moore et al., 2001). Additionally, the researchers found that the pandemic H1N1 virus 
was able to replicate within lung tissue more effectively than seasonal influenzas.  
 In another study conducted on ferrets, researchers found that in comparison to 
seasonal influenzas, the pandemic H1N1 virus caused higher levels of inflammatory 
cytokines such as IL-6, TNF-, and IFN- (Kang, Song, Lee, Kim, & Seo, 2011).  
Levels of alveolar macrophages and lymphocytes were significantly higher in pandemic 
H1N1-infected ferrets in comparison to both seasonal influenza and control ferrets five 
days post-injection (Appendix: Figures – Figure 5), suggesting a stronger immune 
response. In similarity with other studies, Kang et. al. found that pandemic H1N1 was 
able to replicate in the trachea, bronchi, and bronchioles while the seasonal H1N1 virus 
replicated only in the nasal cavity (Kang et al., 2011), (Moore et al., 2001). This study 
concluded that pandemic H1N1’s ability to invade the lungs and induce pro-
inflammatory cytokines contributed to the increased pathologic signs in infected 
organisms.  
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Acute Respiratory Distress Syndrome Definition and Stages 
 Ashbaugh and colleges first defined ARDS in 1967 and the syndrome has since 
been redefined multiple times with the most recent being the 2012 Berlin definition. The 
Berlin definition is regarded to be the most up to date and most generalizable definition. 
Under this definition, ARDS is defined as having an onset period of 7 days after lung 
injury or worsening respiratory symptoms, bilateral opacities that are consistent with 
pulmonary edema on chest radiograph or chest CT, PaO2/FiO2 ratio of 201-300mmHg for 
mild ARDS, PaO2/FiO2 ratio of 101-200mmHg for moderate ARDS, and PaO2/FiO2 ratio 
of ≤100 mmHg for severe ARDS while on a minimum positive end-expiratory pressure 
(PEEP) or continuous positive airway pressure (CPAP) of 5cm of H2O (Thompson, 
Chambers, & Liu, 2017).  
The characteristic histological finding of a patient with ARDS is diffuse alveolar 
damage (DAD), which varies by the specific phase of ARDS (Meduri, Eltorky, & Winer-
Muram, 1995). Both histological and gross anatomical changes occur in each phase of 
ARDS and are summarized in Appendix: Tables - Table 1 and 2. There are three stages to 
the typical ARDS cycle: the exudative phase of edema and hemorrhage, the proliferative 
phase of organization and repair, and the fibrotic phase end-stage fibrosis (Meduri et al., 
1995). The exudative phase is triggered by either direct or indirect injury such as sepsis, 
pneumonia, or viral infection such as H1N1. Activation of resident alveolar macrophages 
leads to the release of proinflammatory cytokines and chemokines (Thompson et al., 
2017). This immune response triggers neutrophil and monocyte chemotaxis as well as 
diapedesis of neutrophils to move towards the site of the infection. The increased 
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hydrostatic pressure due to the increased blood supply, increased vasculature 
permeability, and hyper-permeable alveolar tissue leads to leakage of proteinaceous fluid 
into the interstitium and alveolar space (Hughes & Beasley, 2016). Loss of epithelial 
integrity, preferential binding by viruses like H1N1, and direct injury from repetitive 
opening and closing of lung units (atelectrauma) contribute to the inactivation of type I 
and type II pneumocytes, denudated basement membranes, and denatured surfactant (Luh 
& Chiang, 2007), (Thompson et al., 2017). Hyaline membranes made of proteins, fibrin, 
and debris will form in the spaces. In conjunction with neutrophil-mediated epithelial 
injury, these mechanisms lead to severely impaired gas exchange, alveolar collapse, and 
atelectasis (Thompson et al., 2017). Atelectasis, which is collapse of portions of the lung, 
can lead to ventilation-perfusion (VQ) mismatch and physiological shunting of blood 
from poorly-ventilated areas to well-ventilated areas (Thompson et al., 2017). 
 The proliferative phase of ARDS is the phase in which an attempt at restoring 
homeostasis occurs. Proliferation of fibroblasts and pneumocyte hyperplasia characterize 
this phase. The fibroblasts migrate to repair the broken alveolar and interstitial spaces and 
there is some epithelial cell regeneration (Thompson et al., 2017). 
 The last phase, the fibrotic phase, is characterized by fibrotic lung architecture, 
and possibility cyst formation. Differing host responses can lead to restoration of lung 
architecture or permanent fibrosis with fibroblasts in airways and alveolar spaces on 
histological examination and collagen deposition (Meduri et al., 1995). Increasing 
fibrosis leads to decreased compliance and increased recoil forces, which make the act of 
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breathing extremely difficult. Not all patients will progress into the fibrotic stage, but if 
they do, long term mechanical ventilation is usually needed (Thompson et al., 2017). 
 Patients will present with typical H1N1 symptoms such as fever, cough, chills, 
with additional respiratory complications such as refractory hypoxemia, tachypnea, or 
dyspnea (Homsi, Milojkovic, & Homsi, 2010). Mortality varies based on stage but 
researchers estimate mortality rates for mild, moderate, and severe ARDS of 27%, 32%, 
and 45%, respectively (Hughes & Beasley, 2016). H1N1, like many other viruses, is able 
to trigger the type of immune responses and processes that lead to ARDS. It has been 
shown that the preferential binding of H1N1 to the receptors in the lower lung can lead to 
ARDS and eventual loss of pulmonary function (Töpfer et al., 2014), (Cheng et al., 
2012).  
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VENTILATORY TREATMENT STRATEGIES FOR LIFE-THREATENING 
H1N1 AND ACUTE RESPIRATORY DISTRESS SYNDROME 
 
 Mechanical ventilation is a critical treatment strategy for the survival of patients 
with severe ARDS. Multiple studies have shown, however; that the possibility for 
ventilation induced lung injury (VILI) cannot be overlooked (Lee & Slutsky, 2001), (Qi 
Liu, Guo, Shan, Lan, & Chen, 2018), (Parekh, Abrams, Brodie, & Yip, 2018). Proper 
tidal volumes (VT), ventilation rates, and pressures are necessary for the survival of the 
patient. 
 
Positive End-Expiratory Pressures (PEEP) 
 PEEP is a mechanism in which a ventilator is set to hold a minimum pressure 
within the airways at the end of expiration. This process helps to recruit lung units and 
can aid in recovery after VQ mismatch and shunting occurs. Many studies have been 
conducted to study the most beneficial PEEP levels. High PEEP levels and large tidal 
volumes can lead to sheer stress and pulmonary barotrauma via the repetitive opening 
and closing of ducts (Muscedere, Mullen, Gan, & Slutsky, 1994). In a study using a rat 
model researchers assessed VILI using no PEEP, PEEP levels below the inflection point 
(Pinf), and PEEP levels above the Pinf (Muscedere et al., 1994). The Pinf is the point within 
a pressure-volume curve where there is an abrupt increase in slope. Muscedere et. al. 
found that the group without PEEP showed VILI predominantly in the bronchioles. The 
group with PEEP levels below Pinf showed decreased compliance after ventilation. 
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Researches posit that this decrease in compliance may be due to neutrophilic destruction 
of surfactant via mechanical ventilation, decreased surfactant by collapsed alveoli, or 
irreversible inactivation of surfactant by compression of surfactant films by over 50% 
(Muscedere et al., 1994). The group with PEEP levels above Pinf also showed VILI, 
predominantly in the alveolar duct regions. Muscedere et. al. showed that changing the 
PEEP levels will change the site of possible VILI, but that PEEP levels above the Pinf 
were the most beneficial to survival in the rat model.  
 In a randomized control trial of 53 ARDS patients by Amato et al researchers 
found that low VT and higher PEEP levels were associated with increases in 28-day 
mortality, success in weaning off of mechanical ventilation, and reduced risk of 
barotrauma associated with VILI (Amato et al., 1998). Conservative strategies included 
low PEEP values (enough to keep PaCO2 between 35-38mmHg) and VT of 12ml/kg and 
the protective strategies included VT <6 ml/kg and PEEP values 2cmH2O above Pinf. 
Overall, it was found that the protective strategies resulted in better outcomes. 
Studies by (Chiumello et al., 2010), (Turani et al., 2010), and (Briel et al., 2010) 
found that higher PEEP levels were associated with better outcomes in terms of 
functional residual capacity (FRC), lung compliance, and survival among patients with 
ARDS. Additionally, the studies by Chimello et al found that among the H1N1 ARDS 
population elevated PEEP levels were beneficial.  
Recruitment strategies using PEEP have been experimented for their efficacy in 
ARDS patients. A recruitment maneuver is one in which an intentional transient increase 
in transpulmonary pressure is applied with the idea that this will open atelectatic alveoli 
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and improve VILI (Paolo Pelosi, Gama de Abreu, & Rocco, 2010). Researchers have 
found, however; that this may also contribute to VILI and impair cardiac output through a 
reduction in venous return as mean thoracic pressure increases (Lim et al., n.d.). (Matos 
et al., 2010) found that using a maximal recruitment strategy by increasing PEEP levels 
from the customary level of 5 cmH2O up to 45 cmH2O was associated with exacerbation 
of VILI in their population of severe ARDS patients.  
While it seems that there is consensus that PEEP levels should be greater than the 
inflection point pressures, there was a general lack of studies conducted on the pandemic 
H1N1 ARDS population in terms of PEEP levels.  
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NON-VENTILATORY TREATMENT STRATEGIES FOR LIFE-
THREATENING H1N1 AND ACUTE RESPIRATORY DISTRESS SYNDROME 
 
Conservative Fluid Management 
 Understanding of Starling forces and the importance of proper fluid management 
in intensive care is imperative for survival of the patient. As hydrostatic pressure rises 
and oncotic pressure falls in ARDS patients, pulmonary edema worsens. Pulmonary 
edema increases the work associated with breathing by decreasing compliance, creates 
hypoxemia through intrapulmonary shunts as a result of alveolar edema, and can cause 
pulmonary arterial hypertension via hypoxemia and pulmonary vascular compression 
(Neamu & Martin, 2013).  Fluid management techniques are used to mitigate these risks 
and complications.  
There has been much research on the effects of positive and negative fluid 
balance in patients diagnosed with ARDS. Positive fluid balance is when fluid 
accumulation or intake is greater than fluid output. Negative fluid balance is when fluid 
output is greater than fluid accumulation or intake. As fluids increase within the body of 
an ARDS patient with compromised endothelial and alveolar integrity, pulmonary edema 
worsens and can eventually lead to cardiovascular strain (Neamu & Martin, 2013), 
(Roch, Guervilly, & Papazian, 2011). While negative fluid balance has been thought to 
improve pulmonary edema, it can also decrease venous return resulting in decreased 
cardiac output. 
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In a randomized control trial of 1,000 patients with acute lung injury, conservative 
and liberal fluid management strategies were compared over 7 days for 60-day mortality 
(The National Heart & Network, 2006). The conservative group experienced restricted 
fluid intake and increased urinary output, while the liberal group experienced increased 
fluid intake and decreased urinary outputs. Results showed that the conservative group 
had lower mean arterial pressure, stroke volume, and cardiac index. The conservative 
group also displayed better lung injury scores, oxygenation indexes, and PEEP, but 
increased creatinine and blood urea nitrogen values. Additionally, metabolic alkalosis and 
electrolyte imbalances occurred at a greater frequency in the conservative group 
compared to the liberal group. Researchers did not find a significant difference in 60-day 
mortality between the conservative and liberal fluid groups, which was the main outcome 
of the study. The researchers did, however; find significantly improved lung function, 
increased number of ICU-free days and organ-failure-free days, and decreased time spent 
on mechanical ventilation in the conservative fluid group as compared to the liberal fluid 
group (The National Heart & Network, 2006).  
While this randomized control trial did not show significant decreases in 60-day 
mortality, a second review of the data found that net negative fluid balance on the 4th day 
was associated with an odds ratio of 0.50 (95% CI, 0.28 – 0.89; p<0.001) for hospital 
mortality, indicating that compared to the positive fluid balance, those with negative fluid 
balance on the 4th day had 50% decreased odds of hospital mortality (Rosenberg, 
Dechert, Park, & Barlett, 2009). 
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With the aim that creating a net negative fluid balance will decrease pulmonary 
edema in patients with severe hypoxemia, clinicians may administer furosemide and/or 
albumin (Napolitano, Park, Raghavendran, & Bartlett, 2010). In a randomized control 
trial of 40 patients with acute lung injury/acute respiratory distress syndrome, researchers 
compared the use of furosemide with albumin or furosemide with placebo for 72 hours 
(Martin et al., 2005). Compared to those in the furosemide with placebo group, those in 
the furosemide and albumin group had significantly better outcomes in terms of increased 
oxygenation, total serum protein, and net fluid loss. By the third day, the PaO2/FiO2 ratio 
increased by 49mmHg in the albumin group while the placebo group decreased by 
13mmHg. Additionally, the albumin group had a net fluid loss of 5,480mL by the third 
day compared to 1,490mL in the placebo group (Martin et al., 2005). This study supports 
the research on the benefits of net fluid loss in ARDS patients, as the use of albumin will 
increase capillary/plasma oncotic pressure and help to draw fluid from the interstitial 
spaces of the lungs back into circulation, thus decreasing the severity of the patient’s 
pulmonary edema.  
Conservative fluid management has been associated with long term cognitive and 
psychiatric morbidities. Mikkelsen et al. conducted a study on 102 patients from the 
Acute Respiratory Distress Syndrome Clinical Trials Network Fluid and Catheter 
Treatment Trial. Researchers found that patients who were placed under conservative 
fluid management strategies while hospitalized were more likely to have cognitive 
impairments (Mikkelsen et al., 2012). Additionally, patients who experienced lower 
partial pressure of arterial oxygen during hospitalization were more likely to have 
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psychiatric impairment. While the researchers agree that more studies should be done on 
this association, it raises awareness of possible adverse side effects long term. Overall, 
however; there appears to be consensus among the literature that conservative fluid 
management strategies were effective in overall outcomes of ARDS patients.  
 
Prone Positioning  
The positioning of a patient, either supine or prone can affect oxygenation and 
overall outcomes in ARDS patients and may create a more uniform ventilation-perfusion 
distribution (Koulouras, Papathanakos, Papathanasiou, & Nakos, 2016). The concepts of 
superimposed pressures, gravity, and shape matching can be used to explain the 
improvements in oxygenation seen in the prone position.  
 
Superimposed Pressures 
 Within the chest cavity, each lung lies in a cavity separate from the other lung. 
The lungs, covered by visceral pleura, and the chest cavity, covered by parietal pleura, 
are separated by the intrapleural space, which is filled with a few milliliters of 
intrapleural fluid. The chest wall is composed of the ribs, diaphragm, intercostal muscles, 
and accessory muscles. Upon inspiration, contraction of the external intercostal muscles 
and the diaphragm work together to expand the volume of the chest cavity. As the 
external intercostal muscles contract, they pull the lower ribs towards the upper ribs, 
expanding the rib cage in both lateral and anterior-posterior directions. As the diaphragm 
contracts in a downward motion, it increases the vertical dimensions of the thorax.  
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Although separate, the lung and the chest wall move as one unit during respiratory 
excursions due to cohesive forces between their pleural surfaces. The lattice arrangement 
of elastin and collagen fibers in the lung contribute to its elastic properties, which allow 
the lungs to expand with the chest wall.  
Compared to atmospheric pressure, the intrapleural pressure, PIP, is usually 
negative because the lung, which adheres to the chest wall, tends to recoil, pulls on the 
intrapleural fluid filled “space” and causes PIP to fall. Larger lung volumes cause greater 
lung recoil forces and lower PIP.  The chest wall also has a compliant structure, but unlike 
the lungs, tends to spring outward. 
In the supine position, there is increased pressure in the dorsal lung due to the 
position of the heart and major vasculature (P. Pelosi, Caironi, Taccone, & Brazzi, 2001). 
A “sponge lung” model is a frequently used model to understand the concept of prone 
positioning. Since ARDS patients present with lung edema, the edema homogeneously 
increases overall lung weight resulting in decreased gas exchange in dependent lung 
regions and compression atelectasis seen by CT (Koulouras et al., 2016). When put in the 
prone position, the effect of heart position is reduced and there is more available lung for 
recruitment (Henderson, Griesdale, Dominelli, & Ronco, 2014). 
 
Gravity 
In the supine position, the dorsal chest wall is on a hard surface and so the 
majority of ventilated areas are in the ventral lung as this is the area with the most room 
for expansion and least compressive force. Gravity creates a gradient in intrapleural 
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pressure and distending pressure, which causes a decrease in alveolar size moving from 
ventral to dorsal lung. Lung edema and superimposed pressures is worsened by the effect 
of gravity in the supine position and gravity in the supine position creates large variation 
in alveolar size. In the prone position, however; the more compliant ventral chest wall is 
on the hard surface. This results in the less compliant dorsal chest wall being utilized to 
alter the intrapleural pressure and expand the lung. Additionally, gravity reverses the 
superimposed pressures and moves the compressive force from dorsal to ventral lung but, 
as discussed previously, this area of lung is smaller in size due to the heart and other 
intrathoracic structures (Kallet, 2015). The overall effect of gravity in the prone position 
creates a more homogenous alveolar inflation distribution (Koulouras et al., 2016) 
(Kallet, 2015) (Appendix: Figures – Figure 6).  
 
Shape Matching 
 There is a difference in shape between the chest wall and the lungs. The 
cylindrical shape of the chest wall creates more available space for expansion of the 
conical-shaped lungs in their upper regions, resulting in a relatively greater expansion of 
nondependent alveolar units when supine (Koulouras et al., 2016). When prone, although 
there is increased compression due to gravity and superimposed pressures, regional 
expansion due to shape matching helps counteract these factors (Luciano Gattinoni, 
Taccone, Carlesso, & Marini, 2013). 
In the supine position, superimposed pressures, gravity, and shape matching all 
act in the same direction towards lesser expansion of dependent alveolar units. In the 
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prone position, shape matching counterbalances these factors and overall there is a more 
homogenous inflation of dependent lung units (Luciano Gattinoni et al., 2013) 
(Appendix: Figures – Figure 7). In ARDS, pulmonary blood flow is relatively 
homogenous with slight preference for distribution to the dorsal lung regions, which 
improves the overall ventilation-perfusion ratio and oxygenation levels (Koulouras et al., 
2016) (Kallet, 2015). 
 In a randomized control trial of 466 patients diagnosed with severe ARDS 
(PROSEVA Trial), researchers compared prone positioning of 16 hours to supine 
positioning to assess 28- and 90-day mortality (Guérin et al., 2013). Among the patients, 
28 (6%) ARDS cases were due to influenza A (H1N1). PaO2/FiO2 ratios were higher 
among those in prone positioning at the third and fifth days of ICU hospitalization. 
Twenty-eight day and 90-day mortality was significantly lower among those in the prone 
position than supine (Appendix: Figure – Figure 8), and the rate of successful intubation 
was significantly higher. This study, however; included the practice of turning the patient 
from prone to supine and back to prone at least once a day. Thus it is difficult to attribute 
the results solely to prone positioning and hence, more research on the potential benefit 
of repositioning is required (Guérin et al., 2013).  
A case report on a 41-year-old male in an Italian ICU diagnosed with H1N1-
associated ARDS highlighted the use of prone positioning when ECMO machines are 
unavailable (Gristina et al., 2010). The patient was exposed to prolonged prone 
positioning for 15 days and significant improvements were noted. This patient was 
originally being treated with enteral Oseltamivir, an anti-viral, but experienced difficulty 
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in intake and absorption of the drug in the prone position. The patient was subsequently 
switched to intravenous Zanamivir to eliminate the problem of position in drug intake. 
This case report highlighted the life-saving ability of prone positioning when ECMO 
machines are unavailable, but also discussed some potential complications that need to be 
taken into account such as the ability of the patient to receive and absorb medications 
when prone  (Gristina et al., 2010).   
The vast majority of studies on prone positioning for ARDS support the use in 
patients early on and with skilled nursing staff (De Jong et al., 2013), (Guérin et al., 
2013), (Agrawal & Goel, 2015), (Davis et al., 2007), (Luciano Gattinoni et al., 2013). 
Some studies, however, found that although prone positioning did increase oxygenation, 
it did not affect overall mortality rates (L. Gattinoni et al., 2001), (Taccone et al., 2009).  
 
EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 
 
 Extra corporeal membrane oxygenation is a complex form of extracorporeal 
technology that utilizes a modified heart-lung machine to provide respiratory and/or 
circulatory support to the most critically ill of patients. This technology allows for gas 
exchange outside of the body and was shown to be a positive rescue strategy for ARDS 
patients during the 2009 H1N1 pandemic (ANZ ECMO Investigators & Davies, 2009), 
(Delaney et al., 2010), (Zangrillo et al., 2013), (Turner et al., 2011), (Noah et al., 2011) 
(Rawal, Kumar, Yadav, & Sujana, 2017), (Kutleša et al., 2014).  
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History  
 Mortality from ARDS is between 34-58% (Peek et al., 2009) and those who 
survive their illness are often left with disabilities, both physical and emotional. As 
previously discussed, there are many downfalls of conventional ventilatory management 
such as volutrauma and other forms of ventilator induced lung injury. The idea of 
reducing ventilator settings to allow the lungs to rest while oxygenation is improved 
using an artificial membrane is appealing in light of these risks.  
The principles applied in extracorporeal membrane oxygenation can be traced 
back to 1944 when Kolff and Berk discovered that blood became oxygenated as it passed 
through a cellophane chamber within an artificial kidney (Kolff et al., 1997). Since then, 
massive advances have been made in the field of extracorporeal life support (ECLS). 
Early studies, however; failed to show significant evidence that would support the use of 
such an invasive and costly treatment strategy (Morris et al., 1994), (Zapol et al., 1979). 
The Conventional Ventilator Support vs Extracorporeal Membrane Oxygenation for 
Severe Adult Respiratory Failure (CESAR) trial, which was conducted on 180 
individuals in the UK, led to the expansion of ECMO usage (Peek et al., 2009). This trial 
found that among those placed on ECMO, 6-month survival without disability was 63% 
compared to 47% in the conventional management cohort (Peek et al., 2009). This, 
combined with the widespread discussions of VILI, led to the expansion of ECMO 
globally.  
ECMO was used as a treatment strategy for neonatal and pediatric traumas, 
cardiovascular stress, and bridge to transplant with some criticism until the outbreak of 
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pandemic influenza A H1N1 in 2009 when its use amplified dramatically (Mosier et al., 
2015). Refractory hypoxemia from ARDS during the pandemic was frequently treated 
with ECMO yielding differing results but an overwhelmingly positive scientific opinion 
(Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) 
Influenza Investigators et al., 2009), (Zangrillo et al., 2013), (Noah et al., 2011), (Kutleša 
et al., 2014).   
 
Types of ECMO set-ups 
 Extracorporeal membrane oxygenation has three set-ups: veno-arterial ECMO 
(va-ECMO), veno-venous ECMO (VV-ECMO), and arterio-venous ECMO (av-ECMO). 
There are different indications for each set up as will be discussed below. A typical 
ECMO circuit includes drainage cannulas, a blood pump, a membrane oxygenator, a heat 
exchanger, and tubing (Ventetuolo & Muratore, 2014).  
 
Veno-Arterial ECMO (va-ECMO) 
 Veno-arterial ECMO provides both hemodynamic and respiratory support through 
the pumping of blood from the venous to arterial side. Blood is drained from a cannula 
inserted in either the inferior vena cava or right atrium, passes through the oxygenator 
and heat exchanger, and is returned through a cannula into either the ascending aorta 
(central ECMO) or femoral artery (peripheral ECMO) (Romano, Mendes, Park, & Costa, 
2017). In this circuit (Appendix: Figures – Figure 9), blood bypasses both the heart and 
lungs as the circuit is in parallel with these organs.  
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 va-ECMO reduces cardiac work and oxygen consumption while at the same time 
returning oxygenated blood to the systemic circulation. As this circuit is in parallel with 
the heart and lungs, it is only minimally decreasing blood flow through these organs and 
thus the final arterial oxygen content will be a mix of the less O2 saturated blood from the 
impaired lungs and the more highly O2 saturated blood from the ECMO set up (Romano 
et al., 2017). Decisions to use peripheral or central va-ECMO set ups should take into 
account the possibility of poorly oxygenated blood circulating in areas further away from 
the return of ECMO-oxygenated blood.  
 
Arterio-Venous ECMO (av-ECMO) 
 Arterio-venous ECMO uses the patient’s own arterial pressure to force blood 
through the gas exchanger and therefore from the arterial to the venous side. Patients in 
av-ECMO must have better cardiac function than those under va-ECMO (Martinez & 
Vuylsteke, 2012). The blood is drained from the femoral artery and is returned into the 
femoral vein. There is no pump in this circuit as the driving force is the patient’s own 
arterial pressure (Appendix: Figures – Figure 10). This circuit, therefore, does not play as 
large of a role in oxygenation as the other forms of ECMO set ups. This circuit’s primary 
goal is to remove CO2, since oxygenated blood is passing from femoral artery to femoral 
vein (Martinez & Vuylsteke, 2012). While this is a relatively simple form of ECMO set 
up, it does not provide cardiovascular support and provides slightly less respiratory 
support than other forms and therefore, should be used in less-severe patients (Ventetuolo 
& Muratore, 2014), (Martinez & Vuylsteke, 2012).  
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Veno-Venous ECMO (vv-ECMO) 
 Veno-venous ECMO, like av-ECMO, does not provide hemodynamic support. 
This circuit removes blood from the venous side and pumps it back into the venous side 
(Appendix: Figures – Figure 11), aiding gas exchange by providing oxygenation while 
the lungs are able to rest (Martinez & Vuylsteke, 2012). Additionally, vv-ECMO is able 
to reduce the complications from VILI as it works outside of the body.  This circuit, 
unlike va-ECMO, is in series with both the heart and lungs. Unlike va-ECMO, the blood 
will continue to pass through the lungs and heart and so it is necessary that the lungs have 
an adequate level of functioning (Martinez & Vuylsteke, 2012). Additionally, vv-ECMO 
has lower risks of thromboembolisms compared to va-ECMO (Martinez & Vuylsteke, 
2012). vv-ECMO is the most widely used for ARDS patients.  
 
ECMO Complications 
 The main complications during ECMO treatment are hemorrhage, infection, and 
neurologic impairments such as stroke. 
 
Hemorrhage  
 Hemorrhage poses a significant risk during ECMO treatment. The large non-
biologic ECMO surface results in thrombotic and inflammatory responses that can lead to 
embolisms (Martinez & Vuylsteke, 2012), (Ventetuolo & Muratore, 2014). Fibrinolytic 
responses also occur and can result in clotting factor deficiencies (Martinez & Vuylsteke, 
2012). To mitigate these risks, the tubing in ECMO circuits is lined with heparin, an 
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anticoagulant, and patients are usually given anticoagulants intravenously. In a 
retrospective cohort study of 36 patients, of which 9 were positive for influenza A H1N1, 
researchers studied 14 patients in a severe hemorrhage group and 22 patients in mild 
hemorrhage group on vv-ECMO (Kreyer et al., 2017). Severe hemorrhage was defined as 
having any intracranial or intraabdominal bleeding, hemorrhage time of 50% while on 
vv-ECMO (meaning patient was hemorrhaging ≥ 50% of the time), needing 2 packed red 
blood cells (RBCs) per day or needing 6 packed RBCs in one transfusion (Kreyer et al., 
2017). The severe hemorrhage group had significantly lower survival rates compared to 
mild hemorrhage groups while on vv-ECMO (43% vs. 91%; p=0.002) (Kreyer et al., 
2017). This study also reported that hemorrhage complications are attributed to the death 
of up to 17% of patients on ECMO, highlighting the need for continued research on 
hemorrhage complications and ways to improve the ECMO circuits.  
 
Infections 
In an article by Biffi et al, researchers reported on the incidence and prevalence 
rates of hospital acquired infections (HAIs) and bloodstream infections (BSIs) during 
ECMO treatment (Biffi et al., 2017). ELSO data shows a prevalence of 21% for infection 
rates among adult patients (Vogel, Lew, Kao, & Lally, 2011), (Bizzarro, Conrad, 
Kaufman, Rycus, & Extracorporeal Life Support Organization Task Force on Infections, 
Extracorporeal Membrane Oxygenation, 2011), but prevalence of HAIs ranged from 9% - 
65% with an average of 32.67% among the literature reviewed by Biffi et al [(Burket, 
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Bartlett, Vander Hyde, & Chenoweth, 1999), (Hsu et al., 2009), (H.-Y. Sun et al., 2010), 
(Pieri et al., 2013) , (Schmidt et al., 2012), (Aubron et al., 2013)]. Prevalence rates of 
BSIs ranged from 3 to 18%, with an average of 13%. Since only prevalence can be 
deduced from ELSO data, researchers analyzed single-center studies for incidence. 
Among the data, they found that incidence rates of HAIs ranged from 11.92 to 75.46 
cases per 1,000 ECMO-days with an average of 41.46, and BSIs ranged from 2.98 to 
20.55 episodes per 1,000 ECMO-days with an average of 17.36. Steiner et al found a 
three-fold risk of death among patients with BSI during ECMO treatment as compared to 
those without BSI, highlighting important ECMO complication to work to limit and treat.  
While the invasive nature of ECMO would naturally result in an increased risk of 
BSIs, the high incidence rates of HAIs presents an area of improvement within ECMO 
care. With a widely understood association between length of hospital stay and BSIs 
(Green et al., 2015), (Kaye et al., 2014), (Różańska, Wałaszek, Wolak, & Bulanda, 2016) 
combined with the fact that those on ECMO treatment are already more likely to have 
increased length of stay, effective infection prevention strategies should be in place. 
 
Neurologic complications  
 Stroke has been a widely regarded complication for patients on ECMO. In a 
retrospective study on 23,951 patients receiving ECMO from 2001 – 2011, researchers 
found that neurologic complications including acute ischemic stroke, intracranial 
hemorrhage, and seizures occurred in 10.9% of the patients (2,604) (Nasr & Rabinstein, 
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2015).  In comparison to patients that did not suffer any neurologic complications, these 
patients had higher rates of discharge to a long-term care facility, longer lengths of stay in 
the hospital, and higher mortality rates. Another study, conducted by Guttendorf et al. 
found that neurologic complications occurred in 60% of their sample of 212 patients on 
ECMO (Guttendorf, Boujoukos, Ren, Rosenzweig, & Hravnak, 2014). It is necessary that 
precautions be taken to prevent neurologic complications and that more research is 
conducted on the association between ECMO and neurologic deficits.  
 
ECMO during 2009 Influenza A (H1N1) Pandemic 
 Prior to the 2009 swine flu pandemic, there was much discussion surrounding the 
proper indications of ECMO and both survival and complication rates for patients. As the 
H1N1 pandemic caused more cases of ARDS globally, there was a surge in ECMO use in 
patients for whom conventional ventilation techniques were ineffective. Extracorporeal 
Life Support Organization (ELSO) is a global consortium of health care institutions that 
support research and development in extracorporeal life support. ELSO supports the 
results of the CESAR trial, which found a 63% survival rate at 6 months in those 
receiving ECMO (Extracorporeal Life Support Organization (ELSO), 2013). ECMO 
usage is associated with significant complications and, as such, is currently reserved for 
the most severe of patients. 
 There are many case series, case reports, and meta-analyses that support the use 
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of ECMO for H1N1 ARDS (Delaney et al., 2010), (Zangrillo et al., 2013), (Turner et al., 
2011), (Noah et al., 2011), (Rawal, Kumar, Yadav, & Sujana, 2017), (Kutleša et al., 
2014). During the pandemic, promising results coming out of Australia and New Zealand 
spread globally. In total, Australia and New Zealand experienced 8 times the amount of 
cases of H1N1 compared to the United States (ANZ ECMO Investigators & Davies, 
2009). Their hospitals were overburdened with flu patients and patients suffering from 
ARDS. The Australia and New Zealand Extracorporeal Membrane Oxygenation 
Influenza Investigator team (ANZ ECMO) studied 68 patients with 2009 influenza 
A(H1N1)–associated ARDS that were treated with ECMO in 15 intensive care units 
(ICUs) between June 1 and August 31, 2009. There were 133 patients with 2009 
influenza A(H1N1)–associated ARDS that were treated with conventional ventilation and 
were not referred for ECMO. While the PaO2/FiO2 ratio for severe ARDS is ≤100 mmHg 
while on a minimum PEEP or CPAP of 5 cmH2O, the mean PaO2/FiO2 ratio among the 68 
patients was 56 (range: 48 - 63) with a PEEP of 18 cmH2O (ANZ ECMO Investigators & 
Davies, 2009). Additionally, the average age was 34.4 (range: 26.6 - 43.1) years. These 
data show the severity of respiratory compromise and the relatively young age among the 
patients selected for ECMO. The average duration of ECMO support was 10 days, and 
the cohort accumulated 828 days on ECMO in total (ANZ ECMO Investigators & 
Davies, 2009). While mortality rates on ECMO have been reported to range from 30-
48%, the mortality rate among the patients in this study was only 21%, likely playing a 
role in the widespread use of ECMO during the H1N1 pandemic (ANZ ECMO 
Investigators & Davies, 2009). 
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 A meta-analysis of 8 studies by Zangrillo et al. included 266 H1N1 ARDS 
patients treated with ECMO (Zangrillo et al., 2013). Similar to the ANZ-ECMO data, the 
median length of ECMO treatment was 10 days and patients had received mechanical 
ventilation for an average of 2 days prior to ECMO (Zangrillo et al., 2013). Mortality 
rates varied significantly among the studies, with Holzgraefe et al. reporting 8% 
(Holzgraefe et al., 2010), Patroniti et al. reporting 32% (Patroniti et al., 2011), and 
Chenaitia et al. reporting 65% mortality (Chenaitia et al., 2011). Zangrillo et al. used 
pooled estimates to calculate their reported estimate of 28% mortality among the 266 
patients on ECMO (Zangrillo et al., 2013).  
 Noah et al. conducted a cohort study using data partly from the Swine Flu Triage 
study and analyzed data from 1 of the 4 ECMO centers in the United Kingdom during the 
pandemic (Noah et al., 2011). Individuals with H1N1-related ARDS who were being 
treated with ECMO were matched with non-ECMO individuals to study survival to 
hospital discharge. Researchers used 3 different matching techniques in order to account 
for differences in demographic, physiologic, or comorbidity factors including age, extent 
of hypoxemia, organ dysfunction, pregnancy, obesity, and use of ventilator settings. 
Among the 59 pairs of ECMO-referred and non-ECMO-referred patients, the relative risk 
of hospital mortality was 0.45 with a 95% confidence interval of 0.26-0.79 and a p-value 
of 0.006, indicating a statistically significant result (Noah et al., 2011). The hospital 
mortality rate among those referred for ECMO was 23.7%, representing a 55% decreased 
risk of hospital mortality in comparison to the non-ECMO-referred patients’ mortality 
rate of 52.5% (Noah et al., 2011). This data is especially interesting as the study utilized 
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matching, allowing for better comparisons between groups but should be interpreted with 
some caution as there is no follow up data post-discharge.  
Complications in these studies were not novel; stroke, hemolysis, and hemorrhage 
were the most frequently cited (ANZ ECMO Investigators & Davies, 2009), (Zangrillo et 
al., 2013), (Noah et al., 2011). While there are varying reported mortality rates from the 
pandemic, the overwhelming majority of studies support the use of ECMO for patients 
with H1N1-associated ARDS.  
 
Future areas for concern 
Access 
 ECMO treatments are conducted at ELSO-approved ECMO centers. ELSO 
reports that of the 160 ECMO centers registered in their system, 126 of the centers are in 
North America (Transonic, 2015). For areas of the world with higher H1N1 rates than the 
US such as New Zealand, Australia, and Southeast Asia, this poses potential problems for 
future pandemics. There is current research into mini, portable ECMO machines and 
potential attachments to dialysis machines that would allow them to function as ECMO, 
both of which appear promising for ECMO expansion (T. Müller et al., 2011).  
Portable, compact ECMO machines 
 Müller et al. published a case report of a 30-year-old female who was successfully 
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treated with a compact and easily portable ECMO device (T. Müller et al., 2011). The 
patient experienced improved gas exchange and improved protective ventilation 
immediately after the start of ECMO, and after being weaned off of ECMO on the 12th 
day was successfully discharged after 21 days in the ICU (T. Müller et al., 2011). 
Authors cited the growing concern for the difficulty in transferring unstable patients to 
ECMO centers, especially in times of medical surge such as a pandemic of the nature 
seen in 2009, as the call to action for increased research and development of portable 
ECMO machines. In a later study of all H1N1-associated ARDS patients treated with 
ECMO in Porto, Portugal, researchers found that with the use of portable and compact 
ECMO machines they were able to have a survival to discharge rate of 60% (Roncon-
Albuquerque et al., 2012). While their sample size was only 10 patients who were 
relatively young (mean of 40 years old), this data also supports the use of portable ECMO 
machines for H1N1-related ARDS.  
 
Cost 
 ECMO is extremely expensive and resource-demanding. The CESAR trial found 
that the mean health care costs per patient were more than twice as high in patients who 
were referred for ECMO compared to patients who were treated with conventional 
techniques in the UK (Peek et al., 2009). This study also points out that while ECMO 
costs are relatively high, cost-effectiveness could be improved if there were decreased 
costs associated with ECMO transport.  
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Ratnani et al report that personnel resources, diagnostic and laboratory tests, 
radiology, ICU and operating room procedures, medications, and blood products all 
contribute to the high cost of ECMO (Ratnani, Tuazon, Zainab, & Uddin, 2018). In a 
systematic review by Harvey et al, researchers found that the average ECMO procedure 
cost $73,122 with the average patient having a total hospital cost of $210,142 (Harvey, 
Gaies, & Prosser, 2015). This may be an area in which portable, miniaturized ECMO 
machines would be of use. 
In an observational study done on the miniaturized ECMO machines used in the 
Porto, Portugal study discussed above, researchers found that 17.6% of direct ICU costs 
were from ECMO-specific costs (Roncon-Albuquerque et al., 2014).  Additionally, 
human resources represented the majority of the intensive care unit (ICU) costs from 
ECMO use, with a breakdown of other costs seen in (Appendix: Tables – Table 3). Mean 
cost per patient per day was 41,721 (€).   
 
ECMO IN FUTURE PANDEMICS 
 Access, cost, complications, and training all play a role in the uncertainty of 
systems and surge capacity for the use of ECMO in future pandemics. The Center for 
Disease Control and Prevention as well as the World Health Organization routinely 
engage in planning exercises for future pandemics, knowing that they are inevitable. The 
2009 H1N1 pandemic was an awakening; not because it was overly fatal, but because it 
spread around the globe so quickly. There is potential for future pandemics that move 
  41 
quickly and are very lethal. The question of whether or not the world is ready to handle a 
pandemic similar in characteristics to the 1918 “mother of all pandemics” remains 
unanswered. Future pandemics, however; will likely continue to manifest in respiratory 
complications and more specifically, ARDS. The 2009 H1N1 experience with ARDS 
highlighted the need for continued research on treatment techniques.  
 Primary prevention, while the goal for global infectious disease management, will 
undoubtedly have weaknesses that influenza will take advantage of in growing to a 
pandemic level. Antigenic shift and antigenic drift continue to pose challenges for 
vaccine research and development, making the task of influenza prevention more 
difficult. Viral reassortment and potential for spillover of viruses from animal to human 
will create new strains of influenza, and the potential for strains to be genetically related 
to the 1918 pandemic remains high. The world is more globalized that ever before and 
transcontinental travel is at an all-time high. It is necessary to inform the public of ways 
to prevent influenza and treatments available if they do become ill. As primary 
prevention mechanisms fail in the context of an influenza pandemic, however; medical 
management becomes all the more important.  
 Non-ventilatory management strategies including conservative fluid management 
and prone positioning have shown uplifting results in the treatment of ARDS (Rosenberg 
et al., 2009), (Napolitano et al., 2010), (Patroniti et al., 2011), (Guérin et al., 2013) 
(Amato et al., 1998), (Chiumello et al., 2010). The 2009 experience showed the severity 
of the patient experience and the need for more intensive ventilatory management 
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techniques when conservative fluid management or prone positioning was not enough. 
Adequate PEEP levels continue to be important, but for the many patients who do not 
respond to ventilation management ECMO continues to be the rescue option. ECMO is 
complicated, costly, requires skilled specialists, and is not available in large numbers. 
Future research on miniature, portable machines and ways to improve the complication 
rates of ECMO is hopeful.  
 There is a general lack of information in the literature regarding systems capacity 
and medical surge in the context of ECMO use for ARDS during a pandemic. 
Undoubtedly, this will be of great importance in the future. The literature has strongly 
shown that ECMO is successful for the treatment of ARDS and that its application during 
the 2009 pandemic was life-saving to many. In the future, ECMO is promising for 
patients who have access to specialized treatment facilities. It is necessary that studies be 
conducted on preparedness and surge capacity using ECMO and that there be continued 
strides made towards decreasing ECMO complications.   
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CONCLUSION 
 The 2009 H1N1 pandemic affected millions and raised awareness about necessary 
interventions for acute pulmonary manifestations of the virus. Acute Respiratory Distress 
Syndrome resulted in loss of life worldwide and it is necessary to learn from this 
unfortunate result. Both non-ventilatory and ventilatory management strategies have 
proven to be effective in the treatment of early stage ARDS. Conservative fluid 
management and negative fluid balances were found to decrease strain and improve 
outcomes in ARDS patients (Neamu & Martin, 2013), (Roch et al., 2011), (Mikkelsen et 
al., 2012). The research supported prone positioning for both more homogenous 
ventilation/perfusion ratios and survival rates, but with some studies finding only benefit 
for oxygenation (Luciano Gattinoni et al., 2013), (Agrawal & Goel, 2015). Overall, 
however, the consensus seemed to support prone positioning for H1N1-associated ARDS 
(Gristina et al., 2010), (Guérin et al., 2013).  Lower tidal volumes and higher PEEP levels 
were found to be the most beneficial combination for survival and reduced lung strain 
(Chiumello et al., 2010), (Turani et al., 2010), (Briel et al., 2010). 
Due to the sheer number of patients and the virus’ preferential aggravation of the 
lower lung, treatment options failed at times during the 2009 pandemic and invasive 
measures such as ECMO were relied upon. ECMO is an invasive, costly, resource-
demanding intervention, but one that proved beneficial. In-hospital mortality rates among 
those referred for ECMO were significantly lower when compared to matched 
participants not referred for ECMO, with those referred experiencing a 55% decrease in-
hospital mortality rate (Noah et al., 2011). Other articles echoed this success, with 
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mortality rates ranging from 8% to 65%, with a pooled estimate of 28% mortality 
(Zangrillo et al., 2013)(Holzgraefe et al., 2010), (Patroniti et al., 2011), (Chenaitia et al., 
2011). 
While complications on ECMO such as stroke, hemorrhage, and infection present 
important areas of concern, the threat of future pandemics makes systems capacity a 
crucial area for additional research. Expanded training programs should target the 
medical providers of the most vulnerable and affected populations, but high costs and 
feasibility issues may hinder progress. The future of medical device engineering, 
particularly in the field of miniature and portable ECMO machines, may bridge the gap in 
access to care by allowing for swift movement of resources to areas in need. Pandemic 
simulations and primary prevention strategies must continue, but as seen in 2009, 
pandemic influenza can and will evade these efforts. Medical providers should be well-
trained to use all measures to manage ARDS on a global scale, including the use of 
potentially lifesaving extracorporeal membrane oxygenation. 
 
 
  
  45 
APPENDIX: FIGURES 
 
 
Figure 1:  Structure of a Hemagglutinin Monomer and Location of the Five Known 
Antibody-Binding Sites in the HA1 Subunit. (Treanor, 2004) 
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Figure 2: Mortality Curves: 1911 vs 1918 (Mitchell et al., 2010) 
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Figure 3: Mortality Curves: 2009, 1918, and Seasonal Flu  (Chang et al., 2010) 
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Figure 4: Three types of ECMO circuits (Ventetuolo & Muratore, 2014) 
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Figure 5: Levels of alveolar macrophages and lymphocytes during H1N1 events (Kang 
et al., 2011) 
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Figure 6: Effect of Prone Positioning (Agrawal & Goel, 2015) 
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Figure 7: Effect of Gravity and Shape Matching on Prone Positioning  (Koulouras et al., 
2016) 
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Figure 8: Kaplan-Meier Plot of the Probability of Survival from Randomization to Day 
90 (Guérin et al., 2013) 
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Figure 9: VA ECMO Circuit (Anand, Jayakumar, Aronow, & Chandy, 2016) 
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Figure 10: AV ECMO Circuit (Anand et al., 2016) 
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Figure 11: VV ECMO Circuit (Anand et al., 2016) 
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APPENDIX: TABLES 
 
 
Table 1: Stages of ARDS (Meduri et al., 1995) 
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Acute phase:  
Diffuse alveolar damage  
Prominent hyaline membranes line alveolar spaces 
Interstitium shows mild edematous widening  
(Hughes & Beasley, 2016) 
 
Proliferative phase:  
Diffuse alveolar damage 
Residual hyaline membrane in the upper right  
Interstitium shows prominent expansion by myxoid 
fibroblastic tissue  
Prominent type 2 pneumocyte hyperplasia  
(Hughes & Beasley, 2016) 
 
Granulation tissue in the distal air spaces with a 
chronic inflammatory-cell infiltrate 
(Ware & Matthay, 2000).  
 
 
 
 
 
 
Table 2: Histological Findings in Stages of ARDS (Hughes & Beasley, 2016), (Ware & 
Matthay, 2000) 
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Table 3: Costs Associated with ECMO (Roncon-Albuquerque et al., 2014) 
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JAMA .................................................... The Journal of the American Medical Association 
NCBI .................................................. The National Center for Biotechnology Information 
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